Sep 30, 2021

Penumbra Q3 2021 Earnings Report

Penumbra reported a revenue increase of 25.8% compared to the third quarter of 2020.

Key Takeaways

Penumbra, Inc. reported financial results for the third quarter ended September 30, 2021, with revenue reaching $190.1 million, a 25.8% increase compared to the third quarter of 2020. The company is increasing its guidance for 2021 total revenue to be in the range of $735 million to $740 million.

Total revenue increased to $190.1 million, a 25.8% increase compared to Q3 2020.

Revenue from vascular products grew by 40.3% to $105.5 million.

Revenue from neuro products grew by 11.5% to $84.7 million.

The company is increasing its guidance for 2021 total revenue to be in the range of $735 million to $740 million, which represents 31% to 32% growth over 2020 revenue.

Total Revenue
$190M
Previous year: $151M
+25.8%
EPS
$0.12
Previous year: $0.06
+100.0%
Gross Margin
63.1%
Previous year: 60.2%
+4.8%
Gross Profit
$120M
Previous year: $90.9M
+31.9%
Cash and Equivalents
$66.3M
Previous year: $80.1M
-17.3%
Free Cash Flow
$30.6M
Previous year: -$7.7M
-497.9%
Total Assets
$973M
Previous year: $810M
+20.1%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

The Company is increasing its guidance for 2021 total revenue to be in the range of $735 million to $740 million, which represents 31% to 32% growth over 2020 revenue of $560.4 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income